Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities.

Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities.
复制标题

DOI:
10.1016/j.stem.2018.05.004
复制
发表时间:
2018-06-01
期刊:
影响因子:
23.9
通讯作者:
Sensébé L
Sensébé L
中科院分区:
医学1区
文献类型:
--
作者:
Galipeau J;Sensébé L

文献摘要

参考文献

被引文献

相似文献

间充质基质细胞(MSC)已经成为临床试验的主题超过一代人,高级临床试验的结果没有达到通过鼓励广泛疾病模型中的临床前动物数据所提出的期望。从这个角度来看,临床前研究和人类转化研究中的重要生物学和药理学差异被强调,临床试验失败和最近成功的分析为MSC监管批准和部署未满足医疗需求的疾病提供了合理的途径。
Mesenchymal Stromal Cells (MSCs) have been the subject of clinical trials for more than a generation and the outcomes of advanced clinical trials have fallen short of expectations raised by encouraging pre-clinical animal data in a wide array of disease models. In this perspective, important biological and pharmacological disparities in pre-clinical research and human translational studies are highlighted, and analysis of clinical trial failures and recent successes provide a rational pathway to MSC regulatory approval and deployment for disorders with unmet medical needs.
DOI: 10.1016/j.celrep.2018.02.013
发表时间: 2018-02-27
期刊: Cell reports
影响因子: 8.8
作者:
Chinnadurai R;Rajan D;Qayed M;Arafat D;Garcia M;Liu Y;Kugathasan S;Anderson LJ;Gibson G;Galipeau J
通讯作者: Galipeau J
DOI: 10.1177/2168479014526877
发表时间: 2014-11-01
影响因子: 1.5
作者:
Hara, Akinori;Sato, Daisaku;Sahara, Yasuyuki
通讯作者: Sahara, Yasuyuki
DOI: 10.1038/bjc.1970.99
发表时间: 1970-01-01
影响因子: 8.8
作者:
FRANKS, LM;CHESTERMAN, FC;ROWLATT, C
通讯作者: ROWLATT, C
DOI: 10.1038/mt.2011.189
发表时间: 2012-01-01
期刊: MOLECULAR THERAPY
影响因子: 12.4
作者:
Francois, Moira;Romieu-Mourez, Raphaelle;Galipeau, Jacques
通讯作者: Galipeau, Jacques
DOI: 10.1016/j.jacc.2013.02.071
发表时间: 2013-06-11
影响因子: 24
作者:
Bartunek, Jozef;Behfar, Atta;Terzic, Andre
通讯作者: Terzic, Andre